Researchers in Iran hope to achieve better outcomes for this vulnerable patient subgroup.
The investigators are working to build on factor VIIa’s established utility to stem bleeding, to one that can also prevent bleeding in both hemophilia A and B patients.
NHF has been leading efforts to fight co-pay accumulator programs since their inception.
Jumo Health and NHF seek to increase health literacy with the release four evidence-based comic books for those managing hemophilia.
The interim trial data for SB-525 included results from the newest and highest dosing group.
PAN Foundation and NHF announce new alliance to provide comprehensive support needed to best manage their disease.
Loss of patient protections would raise barriers to health insurance.
This list is revised annually to include post-secondary educational scholarships that are available to students living with bleeding disorders and their family members.
This new inhibitor kit is designed to improve and standardize the laboratory measurement of FVIII inhibitors, allowing for enhanced diagnosis and routine screening.
A team of physicians and pharmacists analyzed factor dosing of hemophilia patients at the emergency department of Nationwide Children’s Hospital, targeting out-of-range and optimal dosing data and subsequent educational interventions.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car